uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Distribution of haloperidol, risperidone, raclopride and flumazenil in cortex, corpus callosum and striatum
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
2014 (English)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

Introduction The treatment of psychotic disorders uses antipsychotic drugs, acting by blocking dopamine in the brain’s cortex. Most patients experience extrapyramidal side effects because of dopamine blockage in the motor center in the striatum. Antipsychotics show varying degrees of these side effects. Defining the distribution (Vu,brain) of the drug could determine the specific binding,  which could explain the differences. Haloperidol and risperidone and the PET-ligands raclopride and flumazenil were chosen to investigate in this study. PET-ligands used when performing a PET-scan, show the distribution of a certain receptor in different brain regions. Aim The aim of the project was to evaluate the Vu,brain  of haloperidol, risperidone, raclopride and flumazenil in different regions of the brain: cortex, corpus callosum and striatum using the brain slice method, in order to understand if there may be differences in the binding of these drugs in the brain regions. Materials and Method The brain slice method was used. Six slices from a rat brain was cut and put into a buffer containing the drug being investigated. After 5 h incubation a buffer sample was taken. Four slices were dissected and the amount of drug in each region was determined using liquid chromatography tandem mass spectrometry and compared to the amount in an entire brain slice. Results Vu,brain of risperidone in the entire brain slice was 15.3 mL g brain-1. Kp,uu,cell  was 0,76, showing predominant extracellular distribution of risperidone. Discussion The aim was not met due to analytical difficulties, but as the questions formulated in this project are still very relevant, further research is needed. Results could possibly have a large bearing for the practicing clinician, as well as drug developing companies.

Place, publisher, year, edition, pages
2014. , 21 p.
National Category
Pharmaceutical Sciences
URN: urn:nbn:se:uu:diva-237431OAI: oai:DiVA.org:uu-237431DiVA: diva2:767937
Subject / course
Educational program
Bachelor of Science Programme in Pharmacy
Available from: 2014-12-03 Created: 2014-12-02 Last updated: 2014-12-03Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Pharmaceutical Biosciences
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 182 hits
ReferencesLink to record
Permanent link

Direct link